The biggest piece of Mars on Earth is being auctioned off in New York
Why so expensive?
Well, it's not just any rock. It's the largest piece of Mars ever found on Earth.
The Martian rock, known as NWA 16788, will be sold as part of a natural history-themed sale that also includes a juvenile Ceratosaurus dinosaur skeleton that's more than 2 metres tall and nearly 3 metres long.
According to the auction house, the meteorite is believed to have been blown off the surface of Mars by a massive asteroid strike before traveling 225 million kilometres to Earth, where it crashed into Africa's Sahara Desert.
A meteorite hunter found it in the remote Agadez Region of Niger in November 2023, Sotheby's says.
The reddish-brown hunk is about 70% larger than the next largest piece of Mars found on Earth and represents nearly 7% of all the Martian material currently on this planet, Sotheby's says, measuring in at nearly 375 millimetres in length, 279 millimetres in width and 152 millimetres in height.
'This Martian meteorite is the largest piece of Mars we have ever found by a long shot," said Cassandra Hatton, vice chairman for science and natural history at Sotheby's. 'So it's more than double the size of what we previously thought was the largest piece of Mars.'
The rock is a super a rare find. There are only 400 Martian meteorites out of the more than 77,000 officially recognised meteorites found on Earth, Sotheby's says. Hatton asserted that a small piece of it was removed to study it and confirm that it is indeed Martian.
The study found that it is an 'olivine-micro gabbroic shergottite,' formed from the slow cooling of Martian magma. It has a course-grained texture composed primarily of pyroxene, Maskelynite, and olivine, Sotheby's says.
It also has a glassy surface, likely due to the high heat that burned it when it fell through Earth's atmosphere, Hatton said. 'So that was their first clue that this wasn't just some big rock on the ground,' she said.
It's not clear exactly when the meteoroid hit Earth, but testing shows it probably happened in recent years, Sotheby's said.
Also on auction is the juvenile Ceratosaurus skeleton, which was found in 1996 near Laramie, Wyoming in the United States at Bone Cabin Quarry – a gold mine for dinosaur bones.
Specialists assembled nearly 140 fossil bones with some sculpted materials to recreate the skeleton and mounted it so it's ready to exhibit.
The skeleton is believed to be from the late Jurassic period, about 150 million years ago, Sotheby's says. It's auction estimate is anywhere between $4 million (€3.42 million) to $6 million (€5.13 million).
It's unclear if the items will actually sell at these prices, as such items have never been sold at auction before. Sotheby's says whoever ends up purchasing the incredibly rare items is guaranteed to snag a one of a kind piece of history.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
an hour ago
- Forbes
Pharma Companies Pour Billions Into US Manufacturing To Avoid Tariffs
NEW YORK, NEW YORK - MARCH 12: CEO of Eli Lilly and Company David Ricks speaks at the Economic Club ... More of New York on March 12, 2024 in New York City. The U.S. drugmaker Eli Lilly, has made strategic investments in US manufacturing. Pharmaceutical imports are on the chopping block, as President Trump is proposing a 200% tariff to boost domestic production and make pharmaceutical production in the US more competitive. The U.S. imported $212 billion in pharmaceuticals in 2024, making it the 5th most imported product. The deadline for this is August 1. Jena Santoro, Global Head of Research & Analytics at Everstream Analytics, states that the previously reported grace period of approximately one to one and a half years for pharmaceutical companies to relocate their manufacturing operations to the U.S. - before the tariffs take effect - appears to remain in place. This grace period would allow drug manufacturers time to adjust production strategies and investments. Everstream is a provider of AI-based supply chain risk management solutions. Tariffs are being wielded by this administration as leverage to force reciprocity, extract critical concessions, or safeguard national interests. The pharma industry is one in which this leverage appears to have had considerable success. Pharma Make Significant Investments in the US In response to the threat of tariffs, AstraZeneca, British Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, UK, reported on July 22 that it would invest $50 billion in U.S. production. A significant portion of this investment will be allocated to a new manufacturing center in Virginia. Upon completion, this facility will be the company's largest single manufacturing hub. CEO Pascal Soriot said the investment 'underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally.' The company stated that the Virginia plant will anchor its U.S. expansion and serve as a key hub for future pharmaceutical manufacturing. The site will produce small molecules, peptides, and oligonucleotides using AI, automation, and data analytics to optimize production. AstraZeneca's $50 billion plan also includes expansions in Maryland, Massachusetts, Indiana, Texas, and California. The company's goal is to reach $80 billion in revenue by 2030, with half of that expected to come from the U.S. market. Roche, headquartered in Basel, Switzerland, also announced today that it will invest $50 billion into the US. The investment will be made over a five-year period. The company's commitment includes new research and development (R&D) sites, and new and expanded manufacturing facilities in Indiana, Pennsylvania, Massachusetts, and California. Roch says their investments will create more than 12,000 new jobs: 1,000 at Roche and more than 11,000 in support of new US manufacturing capabilities. Their manufacturing investments will include a gene therapy manufacturing facility in Pennsylvania, a new 900,000-square-foot manufacturing facility to support Roche's expanding portfolio of weight loss medicines (the location of this facility has not yet been announced), and a new manufacturing facility for continuous glucose monitoring in Indiana. Once all new and expanded manufacturing capacity comes online, Roche will export more medicines from the US than it imports. Even before the pharma tariff announcement, Eli Lilly (NYSE: LLY) had announced plans to invest $27 billion to build four new production facilities in the US. The goal of this is to strengthen the country's pharmaceutical supply chain. David Ricks, CEO of Eli Lilly, described the planned facilities as "mega sites." Three of Lilly's newly announced sites will be dedicated to producing active pharmaceutical ingredients, which are critical components in drug production. The fourth site will focus exclusively on injectable drugs. China dominates the production of active pharmaceutical ingredients. China's dominant role in producing APIs is widely viewed as a strategic threat, primarily due to the potential for disruptions to the global pharmaceutical supply chain if China chooses to halt these exports as a way of gaining geopolitical leverage. As relations with China fray, these investments will bring significant manufacturing capabilities back to American soil. "The real gap in the supply chain in the US relates to active ingredient availability," David said. "Importantly, two of those [facilities] will be for synthetic chemistries and these, in particular, have been absent from the landscape in the US for some time." BioGen (Nasdaq: BIIB), an American biotechnology company also based in Cambridge, UK, announced on July 21 a much smaller investment. The company will invest $2 billion in its existing manufacturing plants in North Carolina. However, the facility in North Carolina's Research Triangle Park (RTP) was already home to the company's largest manufacturing plants. These facilities produce key therapies for multiple sclerosis and Alzheimer's. However, Biogen remains committed to global manufacturing. 'Biogen's overall global manufacturing supply chain strategy aims at ensuring resilient and high-quality patient supply through robust risk management including geographical risk diversification and dual sourcing.' Pharmaceutical companies' more recent investments in the US have been driven by both incentives and tariff pressures. Merck (NYSE: MRK) started investing more heavily in the US following the 2017 Tax Cuts and Jobs Act. Since then, Merck has invested more than $12 billion into strengthening its US-based manufacturing and R&D infrastructure. The company plans to invest an additional $9 billion in domestic operations by 2028. Will the Tariffs Go Into Effect? Some of these planned investments are likely to be delayed or not implemented if the tariffs don't occur. The International Emergency Economic Powers Act grants the U.S. President broad authority to regulate economic transactions during a declared national emergency stemming from foreign threats. Traditionally, IEEPA has been used to impose sanctions and freeze assets, but the Trump administration has leveraged it to impose tariffs. This has created legal challenges. The next appellate hearing on the Trump administration's use of IEPPA is on July 31st. However, if the administration loses, TD Cowen expects them to expand its use of Section 232. This national security statute is designed to shield vital industries. These 'sector' tariffs have been announced for steel, aluminum & global autos/parts. Open investigations are focused on copper, lumber, semi-trucks and parts, critical minerals, aircraft & jet engines, and pharmaceuticals. TD Cowen is a US multinational investment bank and financial services division of TD Securities.
Associated Press
5 hours ago
- Associated Press
Looking Back to the Future: Gilead's Long-Standing Commitment To Help End the HIV Epidemic
In June 1981, news of a mysterious disease first began making headlines out of San Francisco, Los Angeles and New York. People who were impacted developed unusual infections and grew sick as their immune systems failed. Those early days of what we now know as the HIV epidemic were marked by great fear and loss. By the time the first medicine was introduced in the United States in 1987, more than 5,000 people had died and the number of people impacted continued to balloon. In the decades since then, Gilead has been committed to relentless innovation to treat and prevent HIV – and its scientific advances have helped reshape the course of the epidemic: The company created the first single-tablet daily HIV treatment in 2006. Prior to this innovation, the first therapies to treat HIV required people to often take more than 20 pills a day and deal with potentially numerous side effects. Six years later, in 2012, Gilead again brought another tool to fight the epidemic when its first HIV prevention medicine was approved. Still a host of social factors, including stigma and access, have continued to contribute to the human toll and economic impact that HIV has had around the world. In the U.S. alone, 100 people die from HIV-related illnesses and 700 people are newly diagnosed each week. Thus, Gilead remains steadfastly committed to helping end the epidemic. Gilead is at the forefront of pioneering innovations in HIV, providing prevention and treatment options that help meet unmet needs. The company closed out 2024 earning the Breakthrough of the Year honor by Science magazine for one of its innovations in HIV. For Gilead, this new chapter of innovation in HIV is driven by two primary themes: putting people first and long-acting prevention options. Putting people first means, in part, partnering with communities early in the clinical development process. Researchers worked with the community in the design of its groundbreaking PURPOSE HIV prevention program. For example, researchers worked with the community in the design of its groundbreaking PURPOSE HIV prevention program, which is considered to be the most comprehensive and diverse of any HIV prevention program conducted. 'To make substantial progress, we must be intentional about both the scientific and community-based factors that help shape the epidemic,' says Moupali Das, Vice President, Clinical Development, HIV Prevention & Pediatrics. 'It's critical to focus on groups who are disproportionately affected by HIV and who most need new options for prevention.' Gilead also goes beyond investing in world-class science and putting people at the center of the drug development process. It also works with community organizations and global partners to reduce barriers to care and help enable access to its medicines. 'To help stop HIV, we need to help enable access to our medicines to everyone who could benefit, no matter who or where they are,' says Janet Dorling, Senior Vice President, Intercontinental Region, and Gilead Patient Solutions (GPS). Staying true to the company's heritage of pioneering access programs, Gilead is committed to supplying its medicines where the need is greatest. Ultimately, it will take a combination of bold, scientific innovation coupled with partnerships to help end the epidemic that has taken the lives of more than 42 million people since the 80s. 'We have a responsibility to help end one of the greatest public health challenges of our time,' says Daniel O'Day, Chairman and Chief Executive Officer. 'The opportunity to end the HIV epidemic has never been greater.' Originally published by Gilead Sciences Visit 3BL Media to see more multimedia and stories from Gilead Sciences
CNET
10 hours ago
- CNET
Nano-Hydroxyapatite Toothpaste: The Benefits and Risks of the Fluoride-Free Alternative
As health concerns around fluoride in public drinking water continue to swirl, nano-hydroxyapatite toothpastes are becoming increasingly popular substitutes for fluoride toothpaste. Popular brands include Boka Davids and NOBS (No Bad Stuff), which are touted as fluoride-free alternatives that whiten teeth, repair enamel and prevent cavities. "As ingredient labels shift toward cleaner, fluoride-free formulas, one compound is taking center stage in modern oral care: nano-hydroxyapatite," Dr. Pia Lieb, DDS, cosmetic dentist and clinical assistant professor emerita at NYU College of Dentistry, explains. If you're thinking about replacing your fluoride toothpaste with a nano-hydroxyapatite alternative, this is what dental experts want you to know before you brush your teeth. What is nano-hydroxyapatite? "Nano-hydroxyapatite is a synthetic calcium phosphate compound that's used in some oral care products, including toothpastes," explains Dr. Ada Cooper, consumer advisor and spokesperson for the American Dental Association, says. "[It] has a structure that is similar to hydroxyapatite found in enamel, and nHAP gets incorporated into the tooth structure preferentially in demineralized areas." Nano-hydroxyapatite is also abbreviated as n-HA and n-HAp. Dr. Royce Lai of King Village Dental adds that this is technically a two-part question, since "hydroxyapatite has been around for decades and has been studied for at least 20 years." Newer and less studied, nano-hydroxyapatite is a version of hydroxyapatite with small, rod-shaped particles. "Hydroxyapatite is natural. It is a type of calcium that makes up bones and teeth," says Lai. "Nano-hydroxyapatite relates to the particle size. These are between 20 and 80 nanometers and are much smaller than the hydroxyapatite tubules that are a part of your teeth." According to Dr. Daniela Eversgerd, a cosmetic dentist and the founder of Allure Dental, nano-hydroxyapatite was developed by NASA in the 1970s for astronauts dealing with bone and enamel loss during long periods of space travel. Since the early 1990s, it has been approved for oral care products in Japan. Nano-hydroxyapatite toothpaste benefits "Nano-hydroxyapatite doesn't just protect your teeth -- it helps rebuild them," says Dr. Catrise Austin, a cosmetic dentist, author of Gum Health Made Simple and host of the Let's Talk Smiles podcast. She lists the following as potential nano-hydroxyapatite benefits: Enamel remineralization Tooth sensitivity relief Reduced bacterial adhesion Whitening and gloss enhancement "n-HA can actually fill microscopic cracks and help reverse or arrest early cavities," adds dentist Dr. Sandip Sachar. Austin cites a 2019 study that found a 10% hydroxyapatite toothpaste is equivalent or non-inferior to fluoride toothpaste for preventing and remineralizing dental cavities (or caries) in children. When it comes to teeth sensitivity, Lai cites a 2014 study concluding that 15% nano-hydroxyapatite helped sensitive teeth. "The particle size could get into space and work better than larger particles in micro-hydroxyapatite or fluoride," he explains. "The conclusion was that nano-hydroxyapatite could significantly reduce tooth sensitivity to hot and cold in two to four weeks of use." Referencing an 18-month 2023 clinical trial finding that a 10% n-HAp toothpaste protected adult teeth from new cavities as well as a standard 1,450-ppm fluoride paste, Dr. Christopher Tolmie, DDS, MBA, of PDS Health, states, "By patching enamel and calming swollen gums, nano-hydroxyapatite may cut off a hidden spark of chronic inflammation linked to heart disease and diabetes." Since nano-hydroxyapatite toothpastes are fluoride free, Dr. Yenile Y. Pinto, DDS, functional and biomimetic dentist and founder of Deering Dental, adds, "It's also been shown to reduce sensitivity and strengthen the enamel surface without the risk of fluorosis." Fluorosis occurs when you get too much fluoride as a child, causing white or brown spots on the teeth. The CDC reports that fluorosis typically doesn't affect tooth function and isn't painful. A 2020 systematic review of 32 studies concluded that "Nano-HA is a relatively novel material with outstanding physical, chemical, mechanical and biological properties that makes it suitable for multiple interventions. It outperformed most of the classic materials used in implantology and surgery, but it should be further investigated for bone engineering and caries prevention therapy." HengleinA 2023 comprehensive review found that, while more long-term studies are needed to establish the safety of regular use, "Nanohydroxyapatite is a promising revolutionary material in the prevention of early carious lesion mainly due to a greater source of free calcium." Ultimately, providing a 2021 review and 2022 scoping review, Cooper concludes, "Although there is some evidence that alternative ingredients, such as [nano] hydroxyapatite, prevent tooth decay by acting as a remineralizing or anti-cavity agent, the studies are preliminary. The only anti-cavity agent recognized by the Food and Drug Administration in its over-the-counter monograph is fluoride, a naturally occurring chemical." Cooper adds that all toothpastes with the ADA Seal of Acceptance contain fluoride. The administration specifically recommends brushing your teeth twice a day with fluoride toothpaste and regularly visiting your dentist. Nano-hydroxyapatite toothpaste risks "According to a [2021] narrative review from Odontology, the official journal of the Society of the Nippon Dental University, so far, there have been no reports of adverse dental or systemic effects of HAP-containing toothpastes because HAP has an excellent biocompatibility," states Cooper. According to Austin, the concern with nano-hydroxyapatite is that, because it's made of nanoparticles, some worry about how much might get absorbed into the body if regularly swallowed. "The European Commission's Scientific Committee raised concerns due to the lack of long-term safety data on ingestion, particularly in children," she says. This has led to temporary nano-hydroxyapatite restrictions (not a full-on banning) in Europe. The European Scientific Committee deems nHA safe in toothpaste up to 29.5% and up to 10% in mouthwash, per Tolmie. However, he states, "Regulators still bar it from breath-spray products to avoid lung exposure, so stick to pastes and rinses." Key concerns around nano-hydroxyapatite, according to Lieb, are: Potential ingestion and systemic absorption, especially in nano form Lack of long-term studies in humans on the cumulative effects Unknown impact of inhalation from aerosol products (not toothpaste) In terms of systemic absorption, Sachar specifies, "Because nano-hydroxyapatite particles are similar in composition to bone mineral, there has been some theoretical concern that if absorbed systemically, they could potentially contribute to unwanted calcifications in soft tissues (like blood vessels or kidneys)." However, she states that this is speculative and not supported by any current clinical nano-hydroxyapatite toothpaste only effective at 10%? "Most clinical formulations of nHA range from 5%-15%, with 10% emerging as the benchmark concentration in several Japanese and European studies," answers Lieb. "This concentration has demonstrated reliable enamel restoration while maintaining product stability and usability." However, she states that newer formulations are experimenting with lower concentrations and enhanced delivery systems (such as encapsulation or synergistic minerals), which may improve efficacy at reduced levels. "The effectiveness isn't just about percentage, it's also about particle quality and how it's delivered to the tooth surface," she explains. Tolmie adds, "Effective repair starts as low as 5% and plateaus around 10-15%. Several studies show that 5% n-HAp can mend enamel dings, divots and dents in the teeth, with benefits leveling off somewhere between 10% and 15%. One review even noted that 5% sometimes beats 10% because fewer particles clump, making them easier to slip into enamel defects; hence, most US brands sit comfortably in the 5-10% sweet spot." We also reached out to Dr. Foti Panagakos, who's a part of Boka's Oral Health Advisory Committee. "While there is a lot of discussion around nano-hydroxyapatite concentration and its effectiveness, what matters most is how it is formulated and the fact that the ingredient is backed by research," he explains. "This includes how nano-hydroxyapatite is stabilized, delivered and supported by other ingredients, which is why at Boka, years were spent working with oral health professionals to ensure our formula delivers on both safety and performance. Each tube of Boka toothpaste contains a precisely balanced concentration of nano-hydroxyapatite -- high enough to deliver measurable benefits and safe for daily use, with a formula that's gentle on dentin." Should people replace fluoride toothpaste with nano-hydroxyapatite? Eversgerd states that it all depends on each person's oral health needs. "Fluoride remains the gold standard for cavity prevention, supported by decades of large-scale, randomized controlled trials," she explains. "However, for patients seeking a fluoride alternative -- whether due to sensitivity, allergies, personal preferences or a desire for a biomimetic approach -- nano-hydroxyapatite provides a scientifically supported option." According to the Academy of Biomimetic Dentistry, a biomimetic approach is one in which damaged teeth are restored using materials mimicking natural teeth in function, strength and appearance. For high-risk patients, Eversgerd recommends fluoride, while she may recommend n-Ha to low-risk or fluoride-averse individuals. Austin seconds this, but adds that she also recommends fluoride toothpaste to children with poor brushing habits or communities with limited dental access. "nHA is a great option, but it's not a one-size-fits-all replacement for fluoride -- yet," Austin says. Lieb explains that nHA may also be a compelling alternative for patients with aesthetic concerns, such as whitening-induced sensitivity, and individuals in preventive care regimens post-restorative treatment. Pinto agrees that it depends on the person, stating, "For most of my patients, especially those with low to moderate cavity risk, nano-hydroxyapatite is an excellent option; gentler on the mouth, less drying and effective at rebuilding early damage. For people with high cavity risk, fluoride might still be the best choice, at least short term. For my high-risk patients, I often recommend a combo toothpaste that includes both ingredients when appropriate." Ultimately, if a patient isn't high risk and has health or safety concerns about fluoride, she thinks hydroxyapatite is a great option. When asked if there's a reason people should choose n-HAp over other anti-cavity toothpastes, Tolmie answers, "No, as long as patients are brushing their teeth with an anti-cavity toothpaste. There are differences in the way an n-HAp toothpaste and a fluoride toothpaste work to prevent decay, and some n-HAp toothpastes may feel smoother on the teeth. But anti-cavity toothpastes as a whole accomplish the same task. Do I wash a car with tap water or bottled water? We know that both of them get the job done." What's most important, according to Tolmie, is that patients ensure they're not swallowing toothpaste. What does the American Dental Association think? Cooper states that the ADA recommends brushing teeth twice daily for two minutes with fluoride toothpaste, as the naturally occurring mineral has been proven to remineralize weakened enamel and reverse early signs of tooth decay. "Additionally, the fluoride you take in from drinking water and other beverages continues to provide a topical benefit because it becomes part of your saliva, constantly bathing the teeth and helping to rebuild weakened tooth enamel," Cooper further explains. "The best scientific evidence has shown that adding fluoride to community water supplies is safe and effective. This is backed by decades of research and recognized by more than 100 health organizations." GoodboyDoes nano-hydroxyapatite toothpaste work? All of the dentists we consulted agree that nano-hydroxyapatite toothpaste works, but in the right context and with the right product. It's also not a miracle cure and should not replace your entire oral care routine, dentist's recommendations or regular appointments. Plus, Eversgerd adds that more long-term, large-scale trials are needed to fully validate whether it's equal to fluoride in preventing cavities. When asked if it's effective, Austin says, "Yes -- particularly for enamel remineralization and sensitivity. In my practice, I've seen patients who switched to nHA toothpaste experience noticeable improvements in comfort, plaque control and surface smoothness. But like any product, it works best when paired with consistent brushing, flossing and professional cleanings." Pinto agrees and has also seen the results firsthand. "It helps remineralize enamel, soothe sensitivity and support a healthier oral microbiome, especially when paired with a good routine (good home hygiene, healthy diet, hydration and nasal breathing)," she explains, noting that it's not a miracle cure, but does offer many benefits. On behalf of the ADA, Cooper echoes Eversgerd's earlier statement: "The use of nano-hydroxyapatite (nHAP) in over-the-counter products is growing, and some evidence shows that nHAP may contribute to remineralization, but the evidence is fairly new and often ambiguous, especially regarding clinical indications. " Do experts recommend nano-hydroxyapatite toothpaste? All of the experts we consulted do recommend nano-hydroxyapatite toothpaste, but only for certain patients. After all, according to Austin, "Nearly half of US adults over 30 have some form of gum disease, and you can't out-toothpaste a bad hygiene routine." Brushing your teeth regularly, flossing and regularly visiting your dentist are still essential, no matter what toothpaste you use. Though Lieb recommends nHA toothpaste for adult patients experiencing post-whitening sensitivity or early enamel erosion, low-caries risk individuals seeking natural alternatives and adults undergoing cosmetic dental work who want to protect their investment with gentle, remineralizing care, she doesn't recommend nano-hydroxyapatite for children with deciduous dentition. "In my professional opinion, fluoride remains the safest and most effective option for all patients under 14," says Lieb. "Its protective effect during the development of permanent dentition is unmatched, and its caries-prevention record is well established." Sachar states that she often recommends it for "patients seeking fluoride-free options, those with mild tooth sensitivity and for children at risk of swallowing fluoride toothpaste." However, she advises that patients with moderate to high cavity risk not fully abandon fluoride. Again, it's important to note that the "ADA recommends that adults brush their teeth twice daily with fluoride toothpaste for at least two minutes each time, or as directed by a licensed dentist," according to Cooper. This is because the proposed benefits of nHAP are fairly new and ambiguous. Getty Images The bottom line Though more research is needed, the dentists we consulted explained that nano-hydroxyapatite toothpaste can be an effective alternative to fluoride -- but only in the right context. The ADA doesn't recommend it. It's also not a miracle cure or a replacement for brushing regularly, flossing and professional dental appointments. If you're considering nano-hydroxyapatite toothpaste, consult your dentist first before making the switch. They know your teeth best and will be able to help you find the best toothpaste for your smile.
